Vanguard Group
AURA icon

Vanguard Group’s Aura Biosciences AURA Stock Holding History

Vanguard Group’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$16M Buy
2,936,538
+46,035
+2% +$273K ﹤0.01% 2727
2025
Q3 		$17.9M Buy
2,890,503
+413,001
+17% +$2.7M ﹤0.01% 2679
2025
Q2 		$15.5M Buy
2,477,502
+525,169
+27% +$3.07M ﹤0.01% 2680
2025
Q1 		$11.4M Buy
1,952,333
+34,603
+2% +$262K ﹤0.01% 2768
2024
Q4 		$15.8M Buy
1,917,730
+112,296
+6% +$1.06M ﹤0.01% 2702
2024
Q3 		$16.1M Buy
1,805,434
+38,024
+2% +$326K ﹤0.01% 2707
2024
Q2 		$13.4M Buy
1,767,410
+80,000
+5% +$586K ﹤0.01% 2760
2024
Q1 		$13.2M Sell
1,687,410
-43,021
-2% -$357K ﹤0.01% 2806
2023
Q4 		$15.3M Buy
1,730,431
+699,337
+68% +$5.92M ﹤0.01% 2713
2023
Q3 		$9.25M Buy
1,031,094
+2,922
+0.3% +$31.4K ﹤0.01% 2932
2023
Q2 		$12.7M Sell
1,028,172
-20,415
-2% -$218K ﹤0.01% 2813
2023
Q1 		$9.73M Buy
1,048,587
+185,007
+21% +$1.92M ﹤0.01% 2949
2022
Q4 		$9.07M Buy
863,580
+257,696
+43% +$3.28M ﹤0.01% 2995
2022
Q3 		$11M Buy
605,884
+170,709
+39% +$2.58M ﹤0.01% 2917
2022
Q2 		$6.17M Buy
435,175
+206,542
+90% +$3.42M ﹤0.01% 3260
2022
Q1 		$5.03M Buy
228,633
+2,375
+1% +$45.2K ﹤0.01% 3526
2021
Q4 		$3.84M Buy
+226,258
New +$4.04M ﹤0.01% 3756

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group's AURA Position: Q4 2025 in Review

Vanguard Group increased its Aura Biosciences (AURA) stake by 1.6% in Q4 2025, buying an estimated $273K and bringing the position to 2,936,538 shares worth $16M. The position accounts for ﹤0.01% of the portfolio, ranked #2727.

Vanguard Group first reported a position in AURA in Q4 2021 and has held it in 17 quarters since. The position peaked at $17.9M in Q3 2025. 117 funds tracked by Wall St. Rank hold AURA as of Q4 2025.

  • Vanguard Group held 2,936,538 shares of Aura Biosciences worth $16M as of Q4 2025.
  • Vanguard Group bought 46,035 Aura Biosciences shares in Q4 2025, an estimated $273K.
  • Aura Biosciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2727 holding.
  • Vanguard Group first reported a position in Aura Biosciences in Q4 2021 and has held it in 17 quarters since.
  • Vanguard Group's Aura Biosciences position peaked at $17.9M in Q3 2025.
  • 117 funds tracked by Wall St. Rank held Aura Biosciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.